The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

(2021) Tiziano Barbui et al.   LEUKEMIA

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

Responding to Covid-19 — A Once-in-a-Century Pandemic?

(2020) Bill Gates   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

(2020) Steven P. Treon et al.   BLOOD

Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission

(2020) Jennifer Lighter et al.   CLINICAL INFECTIOUS DISEASES

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

(2020) Yang Cao et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Clinical and immunological features of severe and moderate coronavirus disease 2019

(2020) Guang Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China

(2020) Giuseppe Lippi et al.   JOURNAL OF MEDICAL VIROLOGY

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

(2020) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

(2020) Pavan K. Bhatraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome

(2020) Elizabeth A Middleton et al.   BLOOD

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

(2020) Carlos Ferrando et al.   INTENSIVE CARE MEDICINE

The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

(2020) Danielle Peterson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

(2020) Andreas Neubauer et al.   LEUKEMIA

Risk factors for death in 1859 subjects with COVID-19

(2020) Lei Chen et al.   LEUKEMIA

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

(2020) Valentina Giudice et al.   Frontiers in Pharmacology

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

(2020) Enrico Capochiani et al.   Frontiers in Medicine

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

(2020) Alessandro M. Vannucchi et al.   LEUKEMIA

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

(2020) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

(2020) Shruti Gupta et al.   JAMA Internal Medicine

Genetic mechanisms of critical illness in Covid-19

(2020) Erola Pairo-Castineira et al.   NATURE

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

(2020) Andre C. Kalil et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

(2015) Sowmya Parampalli Yajnanarayana et al.   BRITISH JOURNAL OF HAEMATOLOGY

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function

(2015) F Perner et al.   LEUKEMIA

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

(2015) R Zeiser et al.   LEUKEMIA

Myeloproliferative Neoplasms

(2015) Ayalew Tefferi et al.   JAMA Oncology

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE